Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia-Reference-Cited by-同舟云学术

Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia

Published:2008-01 Issue:1 Volume:19 Page:128-134
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fianchi L.,Pagano L.,Leoni F.,Storti S.,Voso M.T.,Valentini C.G.,Rutella S.,Scardocci A.,Caira M.,Gianfaldoni G.,Leone G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/1/128/436562/mdm451.pdf

Reference43 articles.

1. Acute myeloid leukemia;Lowenberg;N Engl J Med,1999

2. Management of acute myeloid leukemia in elderly patients;Hiddemann;J Clin Oncol,1999

3. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study;Leith;Blood,1997

4. How I treat older patients with AML;Estey;Blood,2000

5. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults;Expert Opinion on Biological Therapy;2020-10-05

2. LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY;Mediterranean Journal of Hematology and Infectious Diseases;2020-04-27

3. Targeting Leukemia Stem Cells and the Immunological Bone Marrow Microenvironment;Resistance to Targeted Anti-Cancer Therapeutics;2019

4. Targeting Leukemia Stem Cells in the Bone Marrow Niche;Biomedicines;2018-02-21

5. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?;Annals of Hematology;2016-12-23